Genmab inks bispecific antibody deal with Janssen
This article was originally published in Scrip
Executive Summary
As it bids to establish its Duobody technology platform as a gold standard for creating bispecific antibodies, Danish biotech Genmab has entered into a collaboration with the Johnson & Johnson company Janssen Biotech. As part of the deal, Genmab is to receive an upfront payment of $3.5 million (DKK 21 million).